Get the Stockscreener App
5.575
1.00%
0.055
After Hours:
5.97
0.395
+7.09%
Alumis Inc stock is traded at $5.575, with a volume of 1.18M.
It is up +1.00% in the last 24 hours and up +24.16% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$5.52
Open:
$5.52
24h Volume:
1.18M
Relative Volume:
1.75
Market Cap:
$574.43M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.208
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+10.40%
1M Performance:
+24.16%
6M Performance:
-0.80%
1Y Performance:
-37.01%
1-Day Range:
$5.44
$5.73
1-Week Range:
$4.60
$5.73
52-Week Range:
$2.7601
$10.49
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
5.575 | 574.43M | 0 | -238.77M | -216.62M | -26.81 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Will Alumis Inc. continue its uptrendMarket Trend Summary & Community Verified Trade Signals - newser.com
Will Upcoming ONWARD Data Drive Alumis' Stock Forward? - RTTNews
How to manage a losing position in Alumis Inc.Dip Buying & Daily Market Momentum Tracking - newser.com
Alumis Inc. Advances Pipeline Amid Financial Challenges - TipRanks
Real time scanner hits for Alumis Inc. explainedRisk Management & Technical Pattern Based Buy Signals - newser.com
Alumis Bets Big On R&D Despite Growing Losses - Finimize
Alumis Racks Up Losses But Analysts See Big Upside - Finimize
Alumis reports Q3 revenue $2.07M, consensus $3.14M - TipRanks
Biopharmaceutical firm Alumis's Q3 net loss widens - MarketScreener
Alumis Inc. Reports Third Quarter 2025 Financial Results and Highlights Key Clinical Development Milestones - Quiver Quantitative
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - The Manila Times
Analyzing drawdowns of Alumis Inc. with statistical toolsJuly 2025 PostEarnings & Weekly Watchlist for Hot Stocks - newser.com
Is a relief rally coming for Alumis Inc. holdersJuly 2025 WrapUp & Entry Point Strategy Guides - newser.com
Will Alumis Inc. outperform the marketTrade Risk Summary & Stepwise Entry and Exit Trade Signals - newser.com
Will Alumis Inc. stock benefit from upcoming earnings reportsChart Signals & Momentum Based Trading Ideas - newser.com
Momentum divergence signals in Alumis Inc. chartWeekly Gains Summary & Technical Buy Zone Confirmations - newser.com
Is Alumis Inc. a candidate for recovery play2025 Institutional Moves & Weekly Breakout Opportunity Watchlist - newser.com
Alumis Inc expected to post a loss of 92 cents a shareEarnings Preview - TradingView
Will Alumis Inc. stock remain a Wall Street favoriteTrade Exit Summary & High Accuracy Trade Alerts - newser.com
Is Alumis Inc. stock positioned for long term growthJuly 2025 Breakouts & Verified Entry Point Signals - newser.com
Will Alumis Inc. stock benefit from sector rotationJuly 2025 Earnings & Daily Risk Controlled Trade Plans - newser.com
Is Alumis Inc. stock a safe buy before earnings2025 Biggest Moves & High Accuracy Swing Trade Signals - Fundação Cultural do Pará
Alumis (ALMS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Alumis to Participate in Upcoming November Investor Conferences - The Manila Times
Alumis (Nasdaq: ALMS) schedules investor conference webcasts, replays for 90 days - Stock Titan
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):